EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Recursion Pharmaceuticals, Inc. (RXRX) had EBIT Margin of -663.95% for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
$18.55M |
|
$-119.04M |
|
$10.04M |
|
$8.51M |
|
$141.73M |
|
$-123.18M |
|
$4.17M |
|
$-119.01M |
|
$-119.01M |
|
$-119.04M |
|
$-119.04M |
|
$-119.04M |
|
$-119.04M |
|
$-123.18M |
|
$-106.64M |
|
543.00M |
|
543.00M |
|
$-0.22 |
|
$-0.22 |
|
| Balance Sheet Financials | |
$616.02M |
|
$85.84M |
|
$605.69M |
|
$1.22B |
|
$122.92M |
|
$0.09M |
|
$192.98M |
|
$315.90M |
|
$905.81M |
|
$471.43M |
|
$905.81M |
|
561.23M |
|
| Cash Flow Statement Financials | |
$-264.45M |
|
$-2.70M |
|
$78.41M |
|
$753.92M |
|
$561.53M |
|
$-192.39M |
|
$64.74M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.01 |
|
-- |
|
-- |
|
0.00 |
|
0.01 |
|
45.85% |
|
-663.95% |
|
|
EBIT Margin |
-663.95% |
-- |
|
-641.50% |
|
-641.63% |
|
$-265.16M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
0.54 |
|
165.26 |
|
-13.14% |
|
-25.25% |
|
-9.74% |
|
-13.14% |
|
$1.61 |
|
$-0.49 |
|
$-0.49 |
|